Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 44.8598
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 745792413120.0
- FreeCF/Share 0.5421
- PFCF 1530.7726
- PE 63.6754
- Debt/Assets 0.4309
- DivYield 0.0071
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients
Published: February 25, 2025 by: Market Watch
Sentiment: Positive
The drug company is calling on insurers and federal programs to include coverage of obesity as a chronic disease.
Read More
Eli Lilly Unveils Higher Single-Dose Zepbound Vials for $499 a Month
Published: February 25, 2025 by: Barrons
Sentiment: Positive
Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.
Read More
HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?
Published: February 24, 2025 by: 24/7 Wall Street
Sentiment: Negative
The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over.
Read More
This Growth Stock Surged 63% in 2024. Here's Why 2025 Could Bring An Even Bigger Gain.
Published: February 21, 2025 by: 24/7 Wall Street
Sentiment: Positive
The big pharma sector is one that's generally fallen out of favor for many investors over the past few decades, as large healthcare companies have seen slower growth and consolidation hasn't generally provided the kind of upside investors had grown accustomed to over the latter half of the past century.
Read More
Grok 3 makes ideal stock portfolio for 2025
Published: February 21, 2025 by: Finbold
Sentiment: Positive
Artificial intelligence (AI) platforms have been enjoying the spotlight since the original release of ChatGPT in late 2022 and have started gaining increasing traction among investors for apparently outperforming a significant portion of professional managers.
Read More
Eli Lilly bets big on weight-loss pill with $550 million inventory stockpile
Published: February 20, 2025 by: Reuters
Sentiment: Positive
Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in its financial statements, a filing showed on Wednesday.
Read More
Eli Lilly aims to invest in 'big problems hiding in plain sight' using obesity windfall
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are transforming the company. Lilly now has an obligation to take on other challenging diseases like Alzheimer's, ALS and chronic pain, said the the company's Chief Scientific Officer Dan Skovronsky.
Read More
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Published: February 20, 2025 by: CNBC
Sentiment: Positive
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.
Read More
3 Stocks That Could Trounce the Market in 2025
Published: February 17, 2025 by: The Motley Fool
Sentiment: Positive
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Read More
Calls of the Day: Live Nation, Eli Lilly, AT&T, Adobe and Astera Labs
Published: February 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee discuss the latest Calls of the Day.
Read More
LLY Rises More Than 4% in a Week: How to Play the Stock
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Read More
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Published: February 13, 2025 by: MarketBeat
Sentiment: Positive
Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.
Read More
GLP-1 Drugs Drive Growth for Eli Lilly. Is the Stock a Buy?
Published: February 13, 2025 by: The Motley Fool
Sentiment: Positive
After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (LLY 0.92%) announced its full results and reiterated its earlier 2025 forecast. The company has been a big beneficiary of GLP-1 drugs that have seen soaring demand as they have been shown to greatly help with multiple health issues, including weight control.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000